tradingkey.logo

scPharmaceuticals Inc

SCPH
5.670USD
0.0000.00%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
302.16MMarktkapitalisierung
VerlustKGV TTM

scPharmaceuticals Inc

5.670
0.0000.00%

mehr Informationen über scPharmaceuticals Inc Unternehmen

scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.

scPharmaceuticals Inc Informationen

BörsenkürzelSCPH
Name des UnternehmensscPharmaceuticals Inc
IPO-datumNov 17, 2017
CEOMr. John H. Tucker
Anzahl der mitarbeiter162
WertpapierartOrdinary Share
GeschäftsjahresendeNov 17
Addresse25 Burlington Mall Road, Suite 203
StadtBURLINGTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl01803
Telefon16175170730
Websitehttps://www.scpharmaceuticals.com/
BörsenkürzelSCPH
IPO-datumNov 17, 2017
CEOMr. John H. Tucker

Führungskräfte von scPharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Fri, Feb 6
Aktualisiert: Fri, Feb 6
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
9.50%
Weiss Asset Management
5.37%
Lundbeckfond Invest
5.34%
BlackRock Institutional Trust Company, N.A.
4.02%
Andere
64.48%
Aktionäre
Aktionäre
Anteil
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
9.50%
Weiss Asset Management
5.37%
Lundbeckfond Invest
5.34%
BlackRock Institutional Trust Company, N.A.
4.02%
Andere
64.48%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
27.92%
Investment Advisor
17.99%
Private Equity
12.37%
Investment Advisor/Hedge Fund
10.10%
Research Firm
4.68%
Individual Investor
0.36%
Venture Capital
0.12%
Bank and Trust
0.07%
Pension Fund
0.03%
Andere
26.35%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
224
41.16M
76.68%
-3.36M
2025Q3
203
37.70M
70.24%
-12.04M
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
OrbiMed Advisors, LLC
6.06M
11.29%
--
--
Sep 30, 2025
Rubric Capital Management LP
5.10M
9.5%
+499.91K
+10.86%
Sep 30, 2025
Weiss Asset Management
2.88M
5.37%
+2.88M
--
Sep 30, 2025
Lundbeckfond Invest
2.86M
5.34%
+2.86M
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.16M
4.02%
+168.78K
+8.49%
Sep 30, 2025
Tudor Investment Corporation
2.15M
4.01%
+2.15M
--
Sep 30, 2025
Luther King Capital Management Corp.
2.13M
3.96%
-1.41M
-39.90%
Sep 30, 2025
HSBC Global Asset Management (UK) Limited
1.90M
3.54%
+1.90M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
1.59M
2.95%
-76.49K
-4.60%
Sep 30, 2025
Glazer Capital, LLC
1.38M
2.57%
+1.38M
--
Sep 30, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 Growth ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Mehr Anzeigen
Global X Russell 2000 ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Invesco NASDAQ Future Gen 200 ETF
Anteil0%
iShares Russell 3000 ETF
Anteil0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
ProShares Ultra Nasdaq Biotechnology
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Invesco Nasdaq Biotechnology ETF
Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI